Login to Your Account



Financings Roundup

Pearl Prepares for Phase III Push with $65M Series D

By Catherine Shaffer
Staff Writer

Wednesday, November 14, 2012

Pearl Therapeutics Inc.'s consortium of investors returned for a Series D financing round worth $65 million. The funds, provided by lead investor Vatera Capital, along with 5AM Ventures, Clarus Ventures and New Leaf Venture Partners, will support Phase III studies of Pearl's candidate for chronic obstructive pulmonary disease (COPD), PT003.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription